- Home
- DRMA vs IPDN Comparison
DRMA vs IPDN Comparison
Compare DRMA & IPDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- IPDN
- Stock Information
- Founded
- DRMA 2014
- IPDN 2003
- Country
- DRMA United States
- IPDN United States
- Employees
- DRMA N/A
- IPDN N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- IPDN EDP Services
- Sector
- DRMA Health Care
- IPDN Technology
- Exchange
- DRMA Nasdaq
- IPDN Nasdaq
- Market Cap
- DRMA 4.5M
- IPDN 5.4M
- IPO Year
- DRMA 2021
- IPDN 2013
- Fundamental
- Price
- DRMA $6.45
- IPDN $1.83
- Analyst Decision
- DRMA Strong Buy
- IPDN
- Analyst Count
- DRMA 1
- IPDN 0
- Target Price
- DRMA $3.00
- IPDN N/A
- AVG Volume (30 Days)
- DRMA 23.7K
- IPDN 376.7K
- Earning Date
- DRMA 08-11-2025
- IPDN 08-12-2025
- Dividend Yield
- DRMA N/A
- IPDN N/A
- EPS Growth
- DRMA N/A
- IPDN N/A
- EPS
- DRMA N/A
- IPDN N/A
- Revenue
- DRMA N/A
- IPDN $6,508,349.00
- Revenue This Year
- DRMA N/A
- IPDN N/A
- Revenue Next Year
- DRMA N/A
- IPDN N/A
- P/E Ratio
- DRMA N/A
- IPDN N/A
- Revenue Growth
- DRMA N/A
- IPDN N/A
- 52 Week Low
- DRMA $5.74
- IPDN $0.97
- 52 Week High
- DRMA $37.90
- IPDN $11.20
- Technical
- Relative Strength Index (RSI)
- DRMA 43.91
- IPDN 39.57
- Support Level
- DRMA $5.94
- IPDN $2.42
- Resistance Level
- DRMA $7.33
- IPDN $3.06
- Average True Range (ATR)
- DRMA 0.63
- IPDN 0.24
- MACD
- DRMA -0.05
- IPDN -0.12
- Stochastic Oscillator
- DRMA 27.68
- IPDN 4.65
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About IPDN Professional Diversity Network Inc.
Professional Diversity Network Inc is engaged in providing access to networking, training, educational and employment services to its registered users. It has three operating segments: the TalentAlly Network segment, which maintains and operates job board software and hosts career fairs; the National Association of Professional Women (NAPW) segment, which is a women-only professional networking organization; the RemoteMore segment; and Corporate Overhead. The company generates majority of its revenue from TalentAlly Network Segment.